Article
Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Cancer chemotherapy and pharmacology - 1 Oct 2015
Shukuya Takehito, Ko Ryo, Mori Keita, Kato Motoyasu, Yagishita Shigehiro, Kanemaru Ryota, Honma Yuichiro, Shibayama Rina, Koyama Ryo, Shimada Naoko, Takahashi Kazuhisa
Abstract excerpt
PURPOSE: Docetaxel or pemetrexed monotherapy is recommended either as a second-line treatment for non-small cell lung cancer (NSCLC) patients without EGFR mutation or ALK fusion genes or as a third-line treatment for patients with EGFR mutation or ALK fusion. However, efficacy and survival for these two settings have not been compared, leaving it unclear whether these two populations can be included in the same...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.